Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Three University of Oxford spinouts have raised significant investment to scale their companies in vehicle automation, quantum computing and medical imaging respectively.

Oxford Ionics founders
  • Oxbotica, a leader in autonomous vehicle software for businesses, has raised US$140 million 
  • Oxford Ionics, whose innovations are taking quantum computing a step closer to reality, has raised £30 million
  • Perspectum, an AI driven medical imaging company, has raised US$36 million

Perspectum, founded in 2012, is a precision health company which develops medical imaging tools to improve the diagnoses of metabolic diseases and cancer. It was born out of a discovery made by Dr Rajarshi Banerjee, now CEO of Perspectum, when researching how to improve the use of MRI in cardiology for his DPhil at the University of Oxford. Read more about the discovery here.

The new $36 million investment was led by Oppenheimer Holdings and completes the first close of its Series C funding round. This brings the total amount raised since inception to around $120 million.

"This new funding will help us to continue innovating new products that will make healthcare safer by providing non-invasive alternatives to biopsy, totally changing how and when we can see and treat many diseases," says Dr Rajarshi Banerjee, founder and CEO of Perspectum. 

Read about the other two spin-outs and the full story on the University of Oxford website. 

Similar stories

COVID-19 is a leading cause of death in children and young people in the US

A new study led by researchers at the University of Oxford’s Department of Computer Science has found that, between 2021 and 2022, COVID-19 was a leading cause of death in children and young people in the United States, ranking eighth overall. The results demonstrate that pharmaceutical and public health interventions should continue to be applied to limit the spread of the coronavirus and protect again severe disease in this age group.

Three or more concussions linked with worse brain function in later life

Experiencing three or more concussions is linked with worsened brain function in later life, according to new research.

New blood test could save lives of heart attack victims

Researchers in the Department of Physiology, Anatomy and Genetics (DPAG) have developed a blood test that measures stress hormone levels after heart attacks. The test – costing just £10 – could ensure patients receive timely life-saving treatment.

COVID-19 increased public trust in science, new survey shows

A survey of over 2000 British adults has found that public trust in science, particularly genetics, increased significantly during the pandemic. However, those with extremely negative attitudes towards science tend to have high self-belief in their own understanding despite low textbook knowledge.

Gero Miesenböck awarded 2023 Japan Prize

Congratulations to Professor Gero Miesenböck, Department of Physiology, Anatomy and Genetics (DPAG), who has been awarded the 2023 Japan Prize in the field of Life Sciences, together with Professor Karl Deisseroth, for pioneering work in the field of optogenetics.

Major funding for Oxford will help find new cancer treatments

Cancer Research UK and the National Institute for Health and Care Research are investing over £3 million across the next five years into The University of Oxford’s Experimental Cancer Medicine Centre (ECMC). The investment will enable Oxford to expand its portfolio of precision prevention and early detection cancer trials.